Clin2
NCT06664125Possibly a fitRecruiting

New drug for high phosphorus in dialysis patients

Hyperphosphatemia

Part of Hormones & metabolism clinical trials.

This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been on hemodialysis 2 or 3 times a week for at least the last 3 months
  • Your blood phosphorus level is in the range needed for the study
  • You do not have inflammatory bowel disease or irritable bowel syndrome with diarrhea
  • You are not pregnant or breastfeeding
  • You have not had surgery on your parathyroid glands
  • You have not had diarrhea or loose stools in the week before the study starts

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06933472Recruiting· Phase 3
Study of a new phosphate binder for dialysis patients

This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.

Granada Hills, California
NCT06712654Recruiting· Phase 2
Testing AP306 for high phosphate in dialysis patients

This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.

Huntsville, Alabama
NCT03573089Recruiting
Testing higher vs standard phosphate targets in dialysis patients

This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.

Camperdown, New South Wales
NCT07285291Recruiting· Phase 3
Study of a new drug for high phosphorus in dialysis patients

This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.

Tokyo
NCT06800651Recruiting· Phase 2
A new drug for fast-growing polycystic kidney disease

This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.

Beijing, Beijing Municipality
NCT07548853Recruiting· Phase 3
Testing TS-172 to Lower Phosphorus in Peritoneal Dialysis Patients

This study tests whether a new medicine called TS-172 can help lower phosphorus levels in patients on peritoneal dialysis (a type of kidney treatment). High phosphorus can cause bone problems and other complications, so the trial aims to see if this drug works better than current treatments.

Tokyo

Hear when a new Hyperphosphatemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.